Pfizer grabs another breakthrough tag for RSV shot in older adults

Pfizer’s respiratory syncytial virus (RSV) program is piling on the wins. After gaining a breakthrough tag for its maternal vax program earlier this month, the New York pharma has added the same designation for prevention of the virus in older adults.

PF-06482077, or RSVpreF, snagged the FDA tag Thursday to prevent lower respiratory tract infections from RSV in adults aged 60 and over. The designation comes thanks to phase 2a data Pfizer presented on the shot’s safety, immunogenicity and efficacy after a single shot in healthy adults aged 18 to 50.